Company / Tangible Book Value per Share
Viridian Therapeutics, Inc.\DE Tangible Book Value per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
$8.29
FY2024
5-year range
$8.29 / $15.75
FY2020-FY2024
Trend
-16.0%
vs FY2023
Sector context
#63 of 209
Health Care
What the data says
At $8.29, Viridian Therapeutics, Inc.\DE's tangible book value per share ranks #63 of 209 in the Health Care sector. Tangible Book Value per Share has declined for 4 consecutive years, from $33.75 in FY2020 to $8.29 in FY2024.
Based on SEC 10-K filings.
8.29 in FY2024 with a 5-year CAGR of +1.9%.
Declined from $12.31 to $8.29 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- -19.3%
- 5-Year CAGR
- +1.9%
- 10-Year CAGR
- -
Sector benchmark
#63 of 209 in Health CareTop 30% of 209This company $8.29 Sector average $93.47
▼
-91.1% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's tangible book value per share has declined for 4 consecutive years.
- In FY2024, tangible book value per share decreased 16.0% year-over-year.
- Ranks #63 out of 209 companies in the Health Care sector.
- Peak tangible book value per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $8.29 | -16.0% |
| FY2023 | $9.88 | -19.8% |
| FY2022 | $12.31 | -21.8% |
| FY2021 | $15.75 | -53.3% |
| FY2020 | $33.75 | +347.5% |
| FY2019 | $7.54 | +334.8% |
| FY2018 | $1.73 | -96.2% |
| FY2017 | $46.19 | +152.9% |
| FY2016 | -$87.33 | -629.4% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026